

# Poster number (EP13.24)

## Relugolix Combination Therapy: ultrasound morphological changes on endometriosis and adenomyosis

Valentina Colantonio, **Consuelo Russo**, Elvira Nocita, Ilaria Mazzera, Giulia Monaco, Federica Iacobini, Giorgia Soreca, Alfredo Ercoli, Caterina Exacoustos.


### Introduction

To evaluate by transvaginal ultrasound (TVS) morphological changes of pelvic endometriosis and adenomyosis before and during treatment with Relugolix Combination Therapy (CT) (relugolix/estradiol/norethisterone acetate). Symptom variations and quality of life were evaluated during follow-up period.

### Methods

#### 50 premenopausal patients


- Age 12-20 years
- Ultrasound diagnosis of endometriosis/adenomyosis with or without concomitant fibroids
- Treated with Relugolix CT for at least 3 months up to 12 months



Ultrasound and symptoms evaluation were performed at baseline and during treatment (T1: 3-6 months and T2: 7-12 months).

### Results

- Reduction of the number of patients reporting painful symptoms, particularly dysmenorrhea, persisted in only 2 cases.
- Improvement of VAS score, especially for dyspareunia (Fig.1).
  - Reduction of uterine volume and fibroids volume (Fig.2).
- Despite the reduction of uterine volume, direct signs of adenomyosis were still visible at T1 and T2.
  - Reduction of endometrioma in 16% of cases.
- No statistically significant TVS changes in deep infiltrating endometriosis were observed.



**RelugolixCT significantly reduced uterine and fibroid volume and improved pain symptoms. TVS morphological changes in endometriosis and adenomyosis were limited, with only a slight reduction in endometrioma size.**




Fig. 1. Reduction of VAS score for endometriosis related symptoms during treatment with Relugolix CT.




Fig. 2. Uterine and leiomyoma volume reduction during treatment with Relugolix CT.